Bryan Chan(@DrBryanChan) 's Twitter Profileg
Bryan Chan

@DrBryanChan

Foodie, Oncologist, A/Prof, Plant Parent, Amateur Photographer. He/Him. Views are my own. 🦀🩺🪴📷🌈

ID:48835456

calendar_today19-06-2009 21:29:13

454 تغريدات

489 متابعون

690 التالية

Megan Sanders(@MeganSa31833581) 's Twitter Profile Photo

Resurrecting my Twitter account to advertise the TOGA 2024 annual scientific meeting. 3 international speakers, multidisciplinary updates, catching up with peers. Don’t forget to register! thoraciconcology.org.au/education/asm-…

account_circle
Ramy Sedhom, MD(@ramsedhom) 's Twitter Profile Photo

New ASCO Guideline on Palliative Care for Patients with Cancer ascopubs.org/doi/full/10.12…

1. Early referral to SPECIALIZED PC leads to improved QOL, mood, higher likelihood of documenting EOL preferences
2. PC teams are fundamentally interdisciplinary
3. PC benefits caregivers

account_circle
Eric Lim(@ekslim) 's Twitter Profile Photo

MARS 2 - more than 7 years of work, 26 hospitals, expert mesothelioma centres and surgeons in the UK with over 264 patients deaths just published (online first), open access, free to all to read:
sciencedirect.com/science/articl…

account_circle
Thoracic Oncology Group of Australasia(@TOGAANZ) 's Twitter Profile Photo

HERE'S YOUR SIGN...

to listen to the new episode on 'Lung cancer nurses - champions for better patient care' on your walk, run, or drive.

Apple: buff.ly/49OuADM
Spotify: buff.ly/49LxCIS

HERE'S YOUR SIGN... to listen to the new episode on 'Lung cancer nurses - champions for better patient care' on your walk, run, or drive. Apple: buff.ly/49OuADM Spotify: buff.ly/49LxCIS
account_circle
Patrick Forde(@FordePatrick) 's Twitter Profile Photo

Not one, not 2, but 3 lung cancer plenaries at ! Early telemed pall care, the LAURA trial of consolidation osimertinib after CRT for stage 3 EGFR non small cell lung cancer & the ADRIATIC trial of consolidation immunotherapy after CRT for small cell lung cancer!

account_circle
Jarushka Naidoo(@DrJNaidoo) 's Twitter Profile Photo

Pooled 5-yr outcomes of Pembro+Chemo for PDL1<1% metastatic NSCLC JTO & JTO CRR:

- 442pts (KN189, KN407 &China/Japan extensions)
- mOS 0.64, mPFS HR 0.66, 5yr OS 12.5 v 9.3% favors chemo-IO
- g3+ TRAEs 59.1% chemo-IO

IASLC OncoAlert Shirish Gadgeel

jto.org/article/S1556-…

account_circle
soria(@jsoriamd) 's Twitter Profile Photo

Lung cancer in never-smokers represent the 5thleading cause of cancer-related mortality in the world. They are highly enriched for targetable oncogenic alterations, have low TMB, low rates of PD-L1 positivity, & lack mutational signatures. They occur almost exclusively as

Lung cancer in never-smokers represent the 5thleading cause of cancer-related mortality in the world. They are highly enriched for targetable oncogenic alterations, have low TMB, low rates of PD-L1 positivity, & lack mutational signatures. They occur almost exclusively as
account_circle
COSA(@COSAoncology) 's Twitter Profile Photo

Join or renew your COSA membership before 30 April 2024 to get bonus months of membership and a saving! bit.ly/3hXsDLm

Join or renew your COSA membership before 30 April 2024 to get bonus months of membership and a saving! bit.ly/3hXsDLm
account_circle
Bryan Chan(@DrBryanChan) 's Twitter Profile Photo

Access to Oncology Medicines session at highlighting the inequality of access to cancer medicines to low and middle income countries 🌎

Access to Oncology Medicines session at #COSA23 highlighting the inequality of access to cancer medicines to low and middle income countries 🌎
account_circle